0
0
Tokyo, Mar 11 – NEC Corporation has announced a strategic collaboration with Nagasaki University’s DEJIMA Infectious Disease Research Alliance to develop an AI-powered vaccine targeting Severe Fever with Thrombocytopenia Syndrome (SFTS), a potentially deadly tick-borne virus. The project is supported by the Coalition for Epidemic Preparedness Innovations (CEPI), which has pledged funding of up to ¥750 million.
The research will focus on optimizing “Nanoball,” a pioneering mRNA vaccine technology developed by Nagasaki University. This next-generation approach will integrate NEC OncoImmunity’s artificial intelligence (AI) capabilities to identify optimal candidate proteins for the vaccine. SFTS, caused by a Phenuivirus, poses an increasing threat in Japan and across East Asia, making the development of an effective vaccine a high priority.
By encapsulating mRNA within Nanoball particles, scientists aim to improve vaccine stability, enhance immune response, and eliminate the need for ultra-low temperature storage. This advancement could significantly improve vaccine accessibility, especially in remote and resource-limited regions, including developing nations.
CEPI CEO Dr. Richard Hatchett underscored the critical need for pandemic preparedness, stating that this technology aligns with the global “100 Days Mission,” which aims to develop vaccines for emerging outbreaks within three months.
Prof. Takeshi Nagayasu, President of Nagasaki University, expressed enthusiasm for the project, emphasizing the importance of rapid vaccine development in combating infectious diseases. NEC OncoImmunity CEO Dr. Saverio Niccolini reaffirmed the company’s dedication to leveraging AI in the fight against emerging health threats.
If successful, the Nanoball platform could be adapted to create vaccines for other deadly pathogens, including the elusive ‘Disease X,’ a hypothetical future virus with pandemic potential.
Disclaimer: This article is based on current research and developments. The success and widespread availability of the vaccine are subject to ongoing studies, regulatory approvals, and further scientific validation.
